BioCanRx Welcomes Strategic Science Fund Investment



Ottawa, ON, December 6, 2023 – Today, the Honourable François-Philippe Champagne, Canada’s Minister of Innovation, Science and Industry, and the Honourable Mark Holland, Minister of Health, announced support for 24 third-party science and research organizations – including BioCanRx – under the new Strategic Science Fund (SSF).


“On behalf of our network of researchers and partners across the country, we thank the federal government for investing in Canadian immunotherapies and providing hope for cancer patients that one day we can turn all cancers into curable diseases,” said Dr. Stéphanie Michaud, BioCanRx President and CEO.


“This investment will ensure the continuation of BioCanRx’s project pipeline, enabling the delivery of life-saving clinical trials to Canadian cancer patients using made-in-Canada immunotherapies,” continued Dr. Michaud.


Learn more about the announcement here.


About BioCanRx


BioCanRx is Canada’s Immunotherapy Network. Our vision is to turn all cancers into curable diseases. We are a network of scientists, clinicians, cancer stakeholders, academic institutions, NGOs and industry partners working together to accelerate the development of leading-edge immune oncology therapies for the benefit of patients. As a leader in the translation, manufacture and adoption of cancer immunotherapies, we invest in translating world-class technologies from the research lab into clinical trials. BioCanRx provides researchers with access to funding, expertise, training and biomanufacturing facilities. We train and develop the talent needed for a thriving Canadian health biotechnology sector. BioCanRx receives funding from the federal government’s Networks of Centres of Excellence, and support from industry, the provinces and charities. The network is hosted by the Ottawa Hospital Research Institute. BioCanRx